All In Biotech

Drug Trial Radar · NCT03977792

An Open Label Study to Evaluate the Safety and Efficacy of BOR15001L7 for the Treatment of Cold Sores in Patients With Recurrent Herpes Labialis

A Randomized, Open Label, Non-inferiority Study to Compare the Safety and Efficacy of BOR15001L7 to Docosanol 10% in Patients With Recurrent Herpes Labialis

Last checked: Nov 20, 2026Latest source record: Sep 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 164 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

164

Planned (sponsor's estimate)

Start

Sep 2020

Primary completion

Jul 2021

Study completion Jul 2022

Sponsor

Lead sponsor
Laboratoire Boreaderme Inc.Industry
Sponsor type
Industry
Collaborators
Ecogene 21
First posted
Jun 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

BOR15001L7 is a natural product. The primary objective of this study is to demonstrate its non-inferiority to docosanol 10% based on the healing time of cold sores in patients with recurrent herpes labialis.

Conditions

  • Recurrent Herpes Labialis

Interventions

  • BOR15001L7Drug

    BOR15001L7 topically applied to infected area, 5 times a day, until complete healing of the infection.

  • Docosanol Cream 10%Drug

    Comparator product topically applied to infected area, 5 times a day, until complete healing of the infection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The mean change of healing timeTime frame: Day 1 to 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.